Letosteine
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Viscotiol |
Other names | 2-[2-(ethoxycarbonylmethylsulfanyl)ethyl]-1,3-thiazolidine-4-carboxylic acid |
Routes of administration | Oral (gastroresistant capsules) |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.509 |
Chemical and physical data | |
Formula | C10H17NO4S2 |
Molar mass | 279.37 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Letosteine is a mucolytic[1] patented (U.S. patent 6987120) by Piero del Soldato of Milan, Italy.[2] He filed his application in 2000.
References
- ^ Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z (November 2014). "Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial". Die Pharmazie. 69 (11): 842–9. PMID 25985582.
- ^ US 6987120, del Soldato P, "Pharmaceutical compounds", issued 17 January 2006, assigned to Nicox SA